Yunfei Yuan

12.0k total citations · 3 hit papers
187 papers, 8.2k citations indexed

About

Yunfei Yuan is a scholar working on Molecular Biology, Hepatology and Cancer Research. According to data from OpenAlex, Yunfei Yuan has authored 187 papers receiving a total of 8.2k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Molecular Biology, 74 papers in Hepatology and 56 papers in Cancer Research. Recurrent topics in Yunfei Yuan's work include Hepatocellular Carcinoma Treatment and Prognosis (69 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (27 papers) and RNA modifications and cancer (26 papers). Yunfei Yuan is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (69 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (27 papers) and RNA modifications and cancer (26 papers). Yunfei Yuan collaborates with scholars based in China, Hong Kong and United States. Yunfei Yuan's co-authors include Shi‐Mei Zhuang, Binkui Li, Xin‐Yuan Guan, Jun Huang, Hang Su, Xu Teng, Jian‐Hong Fang, Jiliang Qiu, Jian‐Rong Yang and Leilei Chen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Yunfei Yuan

184 papers receiving 8.1k citations

Hit Papers

MicroRNA-101, Down-regulated in Hepatocellular Carcinoma,... 2009 2026 2014 2020 2009 2012 2023 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. MicroRNA-101, Down-regulated in Hepatocellular Carcinoma, Promotes Apoptosis and Suppresses Tumorigenicity
    2009 533 citations Hang Su, Jian‐Rong Yang et al. Cancer Research profile →
  2. TGF-β-miR-34a-CCL22 Signaling-Induced Treg Cell Recruitment Promotes Venous Metastases of HBV-Positive Hepatocellular Carcinoma
    2012 456 citations Yunfei Yuan et al. profile →
  3. TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study
    2023 71 citations Yichuan Yuan, Jiliang Qiu et al. International Journal of Surgery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yunfei Yuan China 51 4.8k 3.7k 1.7k 1.6k 1.1k 187 8.2k
Hu‐Liang Jia China 43 4.6k 1.0× 3.6k 1.0× 2.0k 1.2× 1.3k 0.8× 731 0.7× 92 7.5k
Ai‐Wu Ke China 41 3.7k 0.8× 2.2k 0.6× 1.4k 0.8× 563 0.3× 1.1k 1.0× 93 5.9k
Bo Zhai China 37 3.1k 0.6× 1.4k 0.4× 1.3k 0.8× 889 0.5× 701 0.6× 152 5.4k
Zhi Dai China 38 2.7k 0.6× 1.9k 0.5× 1.7k 1.0× 677 0.4× 719 0.7× 97 5.4k
Jing‐Ping Yun China 41 3.5k 0.7× 2.5k 0.7× 1.6k 1.0× 398 0.2× 548 0.5× 151 5.8k
Won Sang Park South Korea 55 6.3k 1.3× 2.3k 0.6× 2.6k 1.6× 458 0.3× 777 0.7× 217 9.0k
Amaia Lujambio United States 27 4.2k 0.9× 2.8k 0.8× 1.2k 0.7× 536 0.3× 445 0.4× 54 6.1k
Yoichi Furukawa Japan 48 6.5k 1.4× 1.6k 0.4× 2.3k 1.4× 489 0.3× 609 0.6× 183 9.6k
Rachel A. Ridgway United Kingdom 29 3.5k 0.7× 1.2k 0.3× 2.5k 1.5× 808 0.5× 887 0.8× 45 6.3k
Pnina Brodt Canada 46 3.2k 0.7× 2.2k 0.6× 2.5k 1.5× 448 0.3× 359 0.3× 115 6.8k

Countries citing papers authored by Yunfei Yuan

Since Specialization
Citations

This map shows the geographic impact of Yunfei Yuan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yunfei Yuan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yunfei Yuan more than expected).

Fields of papers citing papers by Yunfei Yuan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yunfei Yuan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yunfei Yuan. The network helps show where Yunfei Yuan may publish in the future.

Co-authorship network of co-authors of Yunfei Yuan

This figure shows the co-authorship network connecting the top 25 collaborators of Yunfei Yuan. A scholar is included among the top collaborators of Yunfei Yuan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yunfei Yuan. Yunfei Yuan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
He, Wei, Guoying Wang, Huanwei Chen, et al.. (2024). Regorafenib with immunotherapy versus regorafenib alone as second‐line treatment for hepatocellular carcinoma: A multicenter real‐world study. Cancer Medicine. 13(9). e7236–e7236. 4 indexed citations
3.
Li, Guanghui, Daqin Suo, Tingting Zeng, et al.. (2024). Overexpression of PDSS2-Del2 in HCC promotes tumor metastasis by interacting with macrophages. Cell Death Discovery. 10(1). 506–506. 2 indexed citations
4.
Yuan, Yunfei, et al.. (2024). PD-1 inhibitor (sintilimab) and lenvatinib plus TACE-HAIC as conversion therapy for initially unresectable HCC: A single-arm, phase 2 clinical trial (PLATIC).. Journal of Clinical Oncology. 42(16_suppl). 4123–4123. 3 indexed citations
5.
Wang, Yongjin, Dinglan Zuo, Yi Zeng, et al.. (2024). KLF4 Suppresses the Progression of Hepatocellular Carcinoma by Reducing Tumor ATP Synthesis through Targeting the Mir-206/RICTOR Axis. International Journal of Molecular Sciences. 25(13). 7165–7165. 3 indexed citations
6.
Shi, Yunxing, Kai Li, Yichuan Yuan, et al.. (2024). Comprehensive analysis of m6A modification in immune infiltration, metabolism and drug resistance in hepatocellular carcinoma. Cancer Cell International. 24(1). 138–138. 2 indexed citations
7.
Qiu, Zhiyu, Chenwei Wang, Pinzhu Huang, et al.. (2023). RFX6 facilitates aerobic glycolysis‐mediated growth and metastasis of hepatocellular carcinoma through targeting PGAM1. Clinical and Translational Medicine. 13(12). e1511–e1511. 14 indexed citations
8.
Liang, Jie‐Ying, Haocheng Lin, Jingwen Liu, et al.. (2021). A novel prognostic nomogram for colorectal cancer liver metastasis patients with recurrence after hepatectomy. Cancer Medicine. 10(5). 1535–1544. 10 indexed citations
9.
Yan, Yan, Jiahao Pan, Yonghua Chen, et al.. (2020). Increased dopamine and its receptor dopamine receptor D1 promote tumor growth in human hepatocellular carcinoma. Cancer Communications. 40(12). 694–710. 52 indexed citations
10.
Li, Yan, Shuhai Lin, Lei Li, et al.. (2018). PDSS2 Deficiency Induces Hepatocarcinogenesis by Decreasing Mitochondrial Respiration and Reprogramming Glucose Metabolism. Cancer Research. 78(16). 4471–4481. 34 indexed citations
11.
Chan, Lok-Hei, Stella Chai, Man Tong, et al.. (2017). TP53INP1 Downregulation Activates a p73-Dependent DUSP10/ERK Signaling Pathway to Promote Metastasis of Hepatocellular Carcinoma. Cancer Research. 77(17). 4602–4612. 42 indexed citations
12.
Wang, Yun, Zhiqiang Wang, Feng-Hua Wang, et al.. (2017). The Role of Adjuvant Chemotherapy for Colorectal Liver Metastasectomy after Pre-Operative Chemotherapy: Is the Treatment Worthwhile?. Journal of Cancer. 8(7). 1179–1186. 17 indexed citations
13.
Qiu, Jiliang, Yun Zheng, Jingxian Shen, et al.. (2015). Resection versus ablation in hepatitis B virus−related hepatocellular carcinoma patients with portal hypertension: A propensity score matching study. Surgery. 158(5). 1235–1243. 14 indexed citations
14.
Hong, Jian, Yunfei Yuan, Jianping Wang, et al.. (2014). Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma. Cancer Research. 74(6). 1845–1856. 37 indexed citations
15.
Liu, Ming, Yan Li, Leilei Chen, et al.. (2014). Allele-Specific Imbalance of Oxidative Stress-Induced Growth Inhibitor 1 Associates With Progression of Hepatocellular Carcinoma. Gastroenterology. 146(4). 1084–1096.e5. 34 indexed citations
16.
Wei, Rongrong, Guoliang Huang, Mei-Yin Zhang, et al.. (2013). Clinical Significance and Prognostic Value of microRNA Expression Signatures in Hepatocellular Carcinoma. Clinical Cancer Research. 19(17). 4780–4791. 88 indexed citations
17.
Chan, Tim Hon Man, Chi Ho Lin, Lihua Qi, et al.. (2013). A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma. Gut. 63(5). 832–843. 186 indexed citations
18.
Huang, Pinzhu, Li Wang, Jian Hong, et al.. (2012). LIN28 expression and prognostic value in hepatocellular carcinoma patients who meet the Milan criteria and undergo hepatectomy. Chinese Journal of Cancer. 31(5). 223–232. 15 indexed citations
19.
20.
Su, Hang, Jian‐Rong Yang, Xu Teng, et al.. (2009). MicroRNA-101, Down-regulated in Hepatocellular Carcinoma, Promotes Apoptosis and Suppresses Tumorigenicity. Cancer Research. 69(3). 1135–1142. 533 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hu‐Liang Jia Breakdown of academic impact, for papers by Ai‐Wu Ke Breakdown of academic impact, for papers by Bo Zhai Breakdown of academic impact, for papers by Zhi Dai Breakdown of academic impact, for papers by Jing‐Ping Yun Breakdown of academic impact, for papers by Won Sang Park Breakdown of academic impact, for papers by Amaia Lujambio Breakdown of academic impact, for papers by Yoichi Furukawa Breakdown of academic impact, for papers by Rachel A. Ridgway Breakdown of academic impact, for papers by Pnina Brodt
Rankless by CCL
2026